Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients

What Was Tested

This clinical trial paper looks at Octreotide and Somatostatin.

Recently a new depot preparation of the long-acting somatostatin analogue, lanreotide Autogel was introduced for the treatment of acromegaly.

Like octreotide long-acting repeatable (LAR), it has high binding affinity for the somatostatin receptor subtype SSTR 2 and less binding affinity for SSTR 5.

The researchers hypothesized that the ability to suppress growth hormone (GH) secretion in patients with acromegaly would be similar for these depot preparations.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

Seven patients (mean age+/-S.E.M. 48.4+/-7 years) on long-term octreotide LAR treatment at a monthly injection interval for a mean of 2.8 years were enrolled in the study.

At 2, 4 and 6 weeks after the next injection fasting GH profiles (every 30 min for 3.5 h) and serum IGF-I measurements were measured.

How the Study Was Run

They underwent a GH secretory profile study with 10 min sampling for 24 h, 28 days after an injection.

What Was Measured

PubMed files the paper under topics including Acromegaly, Anti-Inflammatory Agents, Non-Steroidal, Antineoplastic Agents, Hormonal, Human Growth Hormone, Insulin-Like Growth Factor I, Octreotide and Peptides, Cyclic.

What This Means in Plain Language

This is a clinical trial of Octreotide and Somatostatin.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2004 (European journal of endocrinology), a journal based in England.

More context: the Octreotide compound page and the Somatostatin compound page.